NCT00191789 - Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer | Biotech Hunter

Enrollment

65

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Breast Cancer

Interventions

DRUG

gemcitabine

1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)

DRUG

doxorubicin

60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)

DRUG

cisplatin

70 mg/m\^2, IV, every 21 days x 4 cycles (5-8)

PROCEDURE

surgery

Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.

Trial Locations (3)

110029

For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician., Delhi

411001

For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician., Pune

632004

For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician., Vellore